BiotechTube
Bash Biotech

Bash Biotech

San Francisco, United States· Est.
bashbio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2M

Overview

Bash Biotech is a private, preclinical-stage biotech based in San Francisco, applying a dual-platform approach of AI/ML and systems biology to decode host-microbiome interactions for therapeutic discovery. The company has a nascent pipeline targeting major unmet needs in chronic kidney disease, kidney cancer, Alzheimer's, and Parkinson's disease, all in preclinical development. Founded with $1M in seed funding, it is pre-revenue and focuses on building its proprietary data platforms (iNetModels, GutMicroNet) to drive its drug repositioning and target identification efforts.

Neurological DiseasesKidney Diseases

Technology Platform

Integrates multi-omics data with AI/ML and constraint-based metabolic modeling to build interactive platforms (iNetModels, GutMicroNet) for simulating host-microbiome interactions to identify drug targets and repositioning opportunities.

Funding History

1
Total raised:$2M
Seed$2M

Opportunities

Large and growing unmet needs in neurodegenerative and chronic kidney diseases present multi-billion dollar markets.
The drug repositioning strategy offers a potentially faster, lower-cost development pathway compared to novel drug discovery.
The expanding scientific acceptance of the microbiome's role in systemic disease validates the core research focus.

Risk Factors

High scientific risk in validating the microbiome-disease link for specific CNS indications and translating AI predictions into effective therapies.
Financial risk as an early-stage startup with only a seed round disclosed, requiring significant capital to advance programs.
Intense competition in both AI-driven drug discovery and microbiome therapeutics from better-funded entities.

Competitive Landscape

Competes in the crowded AI/ML drug discovery sector against companies like Recursion, Exscientia, and Insilico Medicine, as well as in the microbiome space with players like Seres Therapeutics and Vedanta Biosciences. Differentiation hinges on its specific focus on integrated host-microbiome metabolic modeling for drug repositioning in neurology and nephrology.

More companies in Microbiome Therapeutics →More companies in United States →